Bristol-Myers Squibb Co vs Manhattan Associates Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.92 (market cap $129.94B), while Manhattan Associates Inc trades at $192.85 (market cap $11.38B). The key difference: Bristol-Myers Squibb Co is far larger — about 11.4× Manhattan Associates Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Manhattan Associates Inc pays none. Which is the better fit depends on your goals.
| BMY | MANH | |
|---|---|---|
Market Cap | $129.94B | $11.38B |
Sector | Health | Technology |
52-Week High | $65.89 | $220.19 |
52-Week Low | $42.60 | $120.88 |
Enterprise Value | $163.92B | $11.25B |
Dividend Yield | 3.96% | — |
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
MANH trades at $191.05, down 2.37% on the day, but maintains a bullish technical outlook with strong moving average signals and support near $192. The company reported robust Q2 2026 earnings, beating EPS estimates with $1.39 versus $1.32 expected, driven by 26% cloud revenue growth. However, a legal investigation into fiduciary duties by Rosen Law Firm presents a headwind. Analyst consensus remains strongly bullish with a $210.33 price target and 80% buy ratings.
The stock offers upside potential from consistent earnings beats and cloud momentum, but faces risks from the ongoing legal probe and elevated valuation multiples. Net income is projected to dip slightly in 2026, necessitating careful monitoring of execution against guidance. The current price sits just above key support, with resistance at $199.
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →